Evidence map›Paper›PMID 30929252›Full record

ArticleClinical and experimental immunology2019

Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).

M Çebi, H Durmuş, V Yılmaz, S P Yentür, F Aysal, P Oflazer, Y Parman, F Deymeer, G Saruhan-Direskeneli

Abstract read
In one paragraph

Article in Clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M ÇebiDepartment of Physiology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
H DurmuşDepartment of Neurology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
V YılmazDepartment of Physiology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
S P YentürDepartment of Physiology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
F AysalDepartment of Neurology, Bakirkoy Research and Training Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.
P OflazerDepartment of Neurology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
Y ParmanDepartment of Neurology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
F DeymeerDepartment of Neurology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
G Saruhan-DireskeneliDepartment of Physiology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.ORCID 0000-0002-6903-7173

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A small subset of myasthenia gravis (MG) patients develop autoantibodies against muscle-specific kinase (MuSK), which are predominantly of the immunoglobulin (Ig)G4 isotype. MuSK-MG is strongly associated with HLA-DRB1*14, HLA-DRB1*16 and HLA-DQB1*05. In this study, the possible effects of these HLA associations on MuSK IgG autoantibody or cytokine production were investigated. Samples from 80 MG patients with MuSK antibodies were studied. The disease-associated HLA types were screened in the DNA samples. The IgG1, IgG2, IgG3 and IgG4 titres of the MuSK antibodies and the levels of interleukin (IL)-4, IL-6, IL-17A and IL-10 were measured in the sera. Comparisons were made among the groups with or without HLA-DRB1*14, HLA-DRB1*16 or HLA-DQB1*05. The IgG4 titres of the MuSK antibodies were higher than those of the IgG1, IgG2 and IgG3 isotypes among the whole group of patients. DRB1*14 (+) DRB1*16 (-) patients had higher levels of IgG4 antibodies than those of DRB1*14 (-) DRB1*16 (+) patients. DRB1*14 (+) DRB1*16 (+) patients also had higher levels of IgG4 antibodies than those of DRB1*14 (-) DRB1*16 (+) and DRB1*14 (-) DRB1*16 (-) patients. Higher IL-10 and lower IL-17A levels were measured in DRB1*14 (+) DRB1*16 (-) patients than in DRB1*14 (-) DRB1*16 (-) patients. The higher IgG4 titres of MuSK autoantibodies in patients carrying HLA-DRB1*14 than those in the other patients suggest a role for HLA in the production of the antibodies. The differences in IL-10 and IL-17A support the role of DRB1 in the etiopathogenesis of this autoimmune response.

Indexed as

AdolescentAdultAgedAutoantibodiesAutoimmunityChildFemaleHLA-DRB1 ChainsHumansImmunoglobulin GInterleukin-10Interleukin-17Interleukin-4Interleukin-6MaleMiddle AgedAutoantibodiesHLA-DRB1 ChainsIL10 protein, humanIL17A protein, humanIL4 protein, humanIL6 protein, humanImmunoglobulin GInterleukin-10Interleukin-17Interleukin-4Interleukin-6MUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, CholinergicHLAIgG isotypeMuSKmyasthenia gravis

Identifiers

PMID30929252
PMCPMC6642874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.